

EQUITY RESEARCH

ILPRA RESULTS REVIEW

TP 7.5€
Up/Downside: 34%

La crescita accelera, con contrazione temporanea della marginalità

ILPRA ha pubblicato i risultati semestrali venerdì sera, confermando il proseguimento del suo percorso di crescita con un forte aumento dei ricavi, sostenuto da nuove acquisizioni. La redditività è stata temporaneamente diluita dai costi di strutturazione e dall'integrazione delle società acquisite, ma emergono segnali incoraggianti per il secondo semestre, storicamente il periodo più importante per il gruppo.

ILPRA ha chiuso il primo semestre 2025 con ricavi pari a 34,5 milioni di euro (+28,7% YoY), trainati dalla continua crescita internazionale (69% del totale) e dal buon andamento dei segmenti food e dairy. La crescita organica si è attestata a +21%. L'espansione è stata favorita anche dal crescente peso delle linee integrate e tailormade, che oggi rappresentano circa il 20–30% del fatturato. La società si sta progressivamente posizionando come fornitore di macchinari complessi e di intere sezioni di linee produttive.

La redditività ha risentito dell'aumento del work-in-progress, che ha temporaneamente trattenuto parte della marginalità, nonché dei costi di strutturazione legati all'espansione internazionale: l'EBITDA si è attestato a 5,4 milioni di euro (-8,2% YoY) con un margine del 15,8% (22,1% nel S1 2024). L'utile netto è stato pari a 1,6 milioni di euro (-26,4% YoY). Nonostante ciò, l'indebitamento netto è migliorato a 18,9 milioni di euro (contro 20,1 milioni di fine 2024) grazie a un'efficace gestione del capitale circolante.

Sul piano strategico, ILPRA ha proseguito il rafforzamento del proprio perimetro con l'acquisizione del 90% di Gelmini S.r.l. (specialista nel confezionamento di formaggi), l'apertura di nuove filiali estere e la costituzione della JV TI WRAP per completare l'offerta in ambito flow-pack. Il mercato rimane in una fase di espansione, con volumi in crescita, ad eccezione del segmento beauty che continua a soffrire.

Il primo semestre conferma una forte crescita dei ricavi e una contrazione dei margini che riteniamo quasi interamente recuperabile nel corso dell'anno, con un margine annuale atteso di poco inferiore al 20%. Con l'integrazione di Gelmini e l'avvio operativo delle nuove filiali, ILPRA continua a rafforzare il proprio profilo di crescita e resta una società interessante per il secondo semestre, che storicamente rappresenta la parte più rilevante dell'esercizio (60% del fatturato annuo).

Ribadiamo la nostra raccomandazione di BUY con un target price di €7,5.

TP ICAP Midcap Estimates	12/24	12/25e	12/26e	12/27e
Sales (m €)	69.9	81.2	91.0	103.7
Current Op Inc (m €)	9.8	11.3	14.8	17.4
Current op. Margin (%)	14.0	13.8	16.3	16.8
EPS (€)	0.44	0.49	0.72	0.91
DPS (€)	0.12	0.13	0.20	0.25
Yield (%)	2.1	2.4	3.5	4.5
FCF (m €)	-0.8	1.2	6.4	9.2

Valuation Ratio	12/25e	12/26e	12/27e
EV/Sales	1.1	0.9	0.8
EV/EBITDA	5.7	4.6	3.7
EV/EBIT	7.9	5.7	4.5
PE	11.4	7.8	6.1

Key data

Price (€)	5.6
Industry	Industrial Machinery
Ticker	ILP-IT
Shares Out (m)	12.039
Market Cap (m €)	67.4
Average trading volumes (k shares / day)	13.200
Next event	1H 2025 - 26.09.2025

Source: FactSet

Ownership (%)

Holds Srl	70.5
Free float	29.5

Source: TPICAP Midcap estimates

EPS (€)	12/25e	12/26e	12/27e
Estimates	0.49	0.72	0.91
Change vs previous estimates (%)	-23.38	-6.00	-3.08

Source: TPICAP Midcap estimates

Performance (%)	1D	1 M	YTD
Price Perf	-2.6	8.7	24.4
Rel FTSE Italy	-3.6	8.9	-0.5



Source: FactSet

Consensus FactSet - Analysts:2	12/25e	12/26e	12/27e
Sales	88.2	100.1	100.1
EBIT	14.0	16.4	16.4
Net income	9.2	11.0	11.0





FINANCIAL DATA

Income Statement	12/22	12/23	12/24	12/25e	12/26e	12/27e
Sales	48.7	62.0	69.9	81.2	91.0	103.7
Changes (%)	15.3	27.4	12.7	16.2	12.0	14.0
Gross profit	35.0	41.1	47.2	52.7	58.6	66.2
% of Sales	71.8	66.2	67.5	64.9	64.4	63.8
EBITDA	11.2	13.9	14.7	15.6	18.3	21.1
% of Sales	23.0	22.4	21.0	19.2	20.2	20.3
Current operating profit	8.8	9.3	9.8	11.3	14.8	17.4
% of Sales	18.0	15.0	14.0	13.8	16.3	16.8
Non-recurring items	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	8.8	9.3	9.8	11.3	14.8	17.4
Net financial result	-0.5	-1.9	-1.4	-2.3	-2.1	-1.7
Income Tax	-1.8	-1.9	-1.8	-2.0	-2.7	-3.3
Tax rate (%)	-22.0	-25.0	-21.3	-21.3	-21.3	-21.3
Net profit, group share	5.2	4.0	5.3	5.9	8.6	11.0
EPS	0.43	0.33	0.44	0.49	0.72	0.91
Financial Statement	12/22	12/23	12/24	12/25e	12/26e	12/27e
Goodwill	0.0	0.0	0.0	0.0	0.0	0.0
Tangible and intangible assets	12.3	25.2	29.0	32.5	32.5	32.4
Right of Use	0.0	0.0	0.0	0.0	0.0	0.0
Financial assets	0.5	0.7	0.1	0.1	0.1	0.1
Working capital	17.0	29.5	35.0	38.1	42.0	45.7
Other Assets	0.0	0.0	0.5	0.5	0.5	0.5
Assets	29.9	55.3	64.7	71.1	75.1	78.7
Shareholders equity group	25.9	28.2	38.7	42.5	49.1	57.7
Minorities	3.9	5.9	0.7	2.0	3.4	4.7
LT & ST provisions and others	0.3	0.0	1.2	1.2	1.2	1.2
Net debt	-3.5	15.3	20.1	21.3	17.3	10.9
Other liabilities	3.2	5.9	4.1	4.1	4.1	4.1
Liabilities	29.9	55.3	64.7	71.1	75.1	78.7
Net debt excl. IFRS 16	-3.5	15.3	20.1	21.3	17.3	10.9
Gearing net	-O.1	0.4	0.5	0.5	0.3	0.2
Leverage	-0.3	1.1	1.4	1.4	0.9	0.5
Cash flow statement	12/22	12/23	12/24	12/25e	12/26e	12/27e
CF after elimination of net borrowing costs and taxes	9.4	12.2	14.0	13.9	15.6	17.7
ΔWCR	-3.3	-11.9	-4.8	-3.1	-3.9	-3.7
Operating cash flow	6.1	0.3	9.2	10.8	11.7	14.0
Net capex	-3.8	-13.8	-8.5	-7.3	-3.2	-3.1
FCF	1.8	-14.4	-0.8	1.2	6.4	9.2
Acquisitions/Disposals of subsidiaries	-0.3	0.0	0.5	0.5	0.5	0.5
Other investments	0.2	-0.7	-1.1	-0.6	-0.4	0.0
Change in borrowings	1.1	12.2	2.4	0.0	0.0	0.0
Dividends paid	-2.0	-1.8	-2.0	-1.4	-1.6	-2.4
Repayment of leasing debt	0.0	0.0	0.0	0.0	0.0	0.0
Equity Transaction	-0.3	-0.1	-0.1	0.0	0.0	0.0
Others Change in not such even the year	0.9	2.2	0.5	-1.0	-1.0	-1.0
Change in net cash over the year	2.0	-3.9	0.3	1.0	6.1	8.1
ROA (%)	8.7%	6.0%	6.3%	6.5%	na	na
ROE (%)	21.7%	16.3%	16.8%	16.3%	na	na
ROCE (%)	35.9%	21.0%	18.5%	19.8%	24.1%	27.0%



DISCLAIMER

Analyst certifications

This research report (the "Report") has been approved by Midcap, a business division of TP ICAP (Europe) SA ("Midcap"), an Investment Services Provider authorised and regulated by the Autorité de Contrôle Prudentiel et de Résolution ("ACPR"). By issuing this Report, each Midcap analyst and associate whose name appears within this Report hereby certifies that (i) the recommendations and opinions expressed in the Report accurately reflect the research analyst's and associate's personal views about any and all of the subject securities or issuers discussed herein and (ii) no part of the research analyst's or associate's compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst or associate in the Report.

Methodology

This Report may mention evaluation methods defined as follows:

- 1. DCF method: discounting of future cash flows generated by the company's operations. Cash flows are determined by the analyst's financial forecasts and models. The discount rate used corresponds to the weighted average cost of capital, which is defined as the weighted average cost of the company's debt and the theoretical cost of its equity as estimated by the analyst.
- 2. Comparable method: application of market valuation multiples or those observed in recent transactions. These multiples can be used as references and applied to the company's financial aggregates to deduce its valuation. The sample is selected by the analyst based on the characteristics of the company (size, growth, profitability, etc.). The analyst may also apply a premium/discount depending on his perception of the company's characteristics.
- 3. Assets and liabilities method: estimate of the value of equity capital based on revalued assets adjusted for the value of the debt.
- 4. Discounted dividend method: discounting of estimated future dividend flows. The discount rate used is generally the cost of capital.
- 5. Sum of the parts: this method consists of estimating the various activities of a company using the most appropriate valuation method for each of them, then realizing the sum of the parts.

Conflict of Interests between TP ICAP Midcap and the Issuer

G. Midcap and the Issuer have agreed to the provision by the former to the latter of a service for the production and distribution of the investment recommendation on the said Issuer: Ilpra

History of investment rating and target price - Ilpra



Historical recommendations and target price (-1Y)

Date	Analyst	Old Target Pric	e New Target Price	Closing Price	Old Recommendation	New Recommendation
17 Jun 25 - 08:23:11	Alessio Olmi	€ 7.50	€ 7.50	€ 4.96	Achat	Buy
18 May 25 - 20:12:44	Alessio Olmi	€ 7.50	€ 7.50	€ 4.64	Achat	Buy
31 Mar 25 - 08:14:07	Alessio Olmi	€ 7.50	€ 7.50	€ 4.36	Achat	Buy
29 Jan 25 - 07:56:27	Alessio Olmi	€ 8.00	€ 7.50	€ 3.90	Achat	Buy



Distribution of Investment Ratings

Rating	Recommendation Universe*	Portion of these provided with investment
		banking services**
Buy	78%	69%
Hold	17%	54%
Sell	3%	40%
Under review	1%	100%

Midcap employs a rating system based on the following:

Buy: Expected to outperform the markets by 10% or more over a 6 to 12 months horizon.

Hold: expected performance between -10% and +10% compared to the market over a 6 to 12 months horizon.

Sell: Stock is expected underperform the markets by 10% or more over a 6 to 12 months horizon.

The history of ratings and target prices for the Issuers covered in this report are available on request at https://researchtpicap.midcapp.com/en/disclaimer.



General Disclaimer

This Report is confidential and is for the benefit and internal use of the selected recipients only. No part of it may be reproduced, distributed, or transmitted without the prior written consent of Midcap

This Report is published for information purposes only and does not constitute a solicitation or an offer to buy or sell any of the securities mentioned herein. The information contained in this Report has been obtained from sources believed to be reliable and public, Midcap makes no representation as to its accuracy or completeness. The reference prices used in this Report are closing prices of the day before the publication unless otherwise stated. All opinions expressed in this Report reflect our judgement at the date of the documents and are subject to change without notice. The securities discussed in this Report may not be suitable for all investors and are not intended to recommend specific securities, financial instruments, or strategies to particular clients. Investors should make their own investment decisions based on their financial situation and investment objectives. The value of the income from your investment may vary due to changes in interest rates, changes in the financial and operating conditions of companies and other factors. Investors should be aware that the market price of the securities discussed in this Report may be volatile. Due to the risk and volatility of the industry, the company, and the market in general, at the current price of the securities, our investment rating may not correspond to the stated price target. Additional information regarding the securities mentioned in this Report is available on request.

This Report is not intended for distribution or use by any entity who is a citizen or resident of, or an entity located in any locality, territory, state, country, or other jurisdiction where such distribution, publication, availability, or use would be contrary to or limited by law or regulation. Entity or entities in possession of this Report must inform themselves about and comply with any such restrictions, including MIFID II. This Report is only intended for persons who are Eligible Counterparties or Professional Clients within the meaning of MIFID II regulation. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. The Report is subject to restricted circulation. The research was conducted in accordance with the provisions of the Charter of good practices for sponsored research. Midcap has adopted effective administrative and organizational arrangements, including "information barriers", to prevent and avoid conflicts of interest regarding investment recommendations. The remuneration of financial analysts who participate in the preparation of the recommendation is not linked to the corporate finance activity.